Ab0597 changes in the thyroid hormones in patients with sjogren’s syndrome in dominican republic

Background Sjogren’s syndrome (SS) is an autoimmune chronic where there is a B-cell activation and lymphocytic Infiltration of exocrine glands, this can be primary or secondary and characterised by xerostomia, xerophtalmia and extraglandular manifestations 1 . Thyroid involvement is frequent in patients with SS sharing histological and antigenic characteristics 2 . 10–24% of patients with SS have thyroid involvement, the most common are Hashimoto’s thyroiditis or Grave’s disease are the most frequent autoimmune syndromes. Some reports indicated that Hashimoto’s Thyroiditis and Grave’s disease has an incidence of 4.2% and 3.4% in the patients with SS respectively. A study showed that in patients with SS 45% had changes in the values of thyroid hormones and 24% autoimmune thyroiditis. 3-5 Objectives Determine the changes in the thyroid hormones in patients with Sjogren’s syndrome. Methods A cross-sectional study. The information was collected from the digital records of Hospital Docente Padre Billini Rheumatology department during the period October 2017-January 2018. Inclusion criteria: age ≥to 18 years old, patients with Sjogren’s syndrome according to ACR/EULAR 2016 criteria. Excluded patients who did not thyroid test during the study and patients who have a thyroid disorder under treatment. The data was analysed using SPSS V23 Windows 10. Results 79 cases were reviewed, of which 51 met the inclusion criteria. 98% were women, average age of 45 years, 9.8% had hypothyroidism and 3.9% hyperthyroidism by laboratory tests. 82.3% were euthyroid. 82.3% had anti Ro and anti La, 96% Schirmer test +and 37.2% positive biopsy report for SS. Conclusions In our study, we found that 9.8% of patients with Sjogren’s syndrome could be associated with subclinical hypothyroidism and 3.9% with hyperthyroidism what can mask the clinical manifestations at the time of diagnosis. The screening in high-risk patients such as patients with autoimmune disorders remains important. References [1] Shiboski CH, Shiboski SC, Seror R, et al. 2016 American College of Rheumatology/European League against Rheumatism Classification Criteria for Primary Sjogren’s Syndrome: a consensus and data-driven methodology involving three international Patient cohorts. Arthritis Rheumatol2017; 69:35–45. [2] Jose Rosa Gomez, Jose Miguel Senabre Gallego, et al. Management of extra glandular manifestations of Sjogren’s syndrome. Clinical Rheumatology. 2010; 6 (s2): 6–11 [3] Barragan-Garfias JA, et al. Enfermedades tiroideas autoinmunes y del tejido conectivo. Rev. Med Inst Mex Seguro Soc. 2013; 51(2):e1–5 [4] Tsuboi H, Asashima H, Takai C, et al. Primary and secondary surveys on Epidemiology of Sjogren’s syndrome in Japan. Mod Rheumatol2014; 24:464–70 [5] Sumie Moriyama, Reo Yoshikawa, et al. Clinical, Endocrinological and Immunological Characteristics of Japanese Patients with Autoimmune Polyglandular Syndrome Type 3a. J Endocrinol Metab. 2016; 6(2):46–51 Disclosure of Interest None declared